AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12796019 — intervention group
Group type: EXPERIMENTAL
Intervention: FAC (doxorubicin 500 mg/m², cyclophosphamide 50 mg/m², fluorouracil 500 mg/m²) every 3 weeks for six cycles
Number of subjects: 985
Study 12796019 — intervention group
Group type: COMPARATOR
Intervention: CMF (methotrexate 600 mg/m², cyclophosphamide 60 mg/m², fluorouracil 600 mg/m²) every 3 weeks for six cycles
Number of subjects: 985
Study 12796019 — intervention group
Group type: EXPERIMENTAL
Intervention: FAC
Number of subjects: 985
Study 12796019 — intervention group
Group type: COMPARATOR
Intervention: CMF
Number of subjects: 985
Study 10232210 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured preoperative teaching program
Number of subjects: 0
Study 10232210 — intervention group
Group type: EXPERIMENTAL
Intervention: Video teaching
Number of subjects: 0
Study 8915788 — intervention group
Group type: EXPERIMENTAL
Intervention: Blinded readings of X-rays
Number of subjects: 50
Study 8915788 — intervention group
Group type: EXPERIMENTAL
Intervention: Blinded readings of morphometry
Number of subjects: 50
Study 8915788 — intervention group
Group type: COMPARATOR
Intervention: Unblinded readings of X-rays
Number of subjects: 50
Study 8915788 — intervention group
Group type: COMPARATOR
Intervention: Unblinded readings of morphometry
Number of subjects: 50
Study 1888619 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualised drug information wallet (leaflet group)
Number of subjects: 125
Study 1888619 — intervention group
Group type: COMPARATOR
Intervention: Usual verbal counselling (control group)
Number of subjects: 125
Study 31965675 — intervention group
Group type: EXPERIMENTAL
Intervention: MOtiVational intErviewing InTervention (MOVE IT)
Number of subjects: 26
Study 30196448 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 g kg‐1 BM NaHCO3 (SBC3)
Number of subjects: 10
Study 30196448 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 10
Study 30196448 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 g kg‐1 BM NaHCO3 (SBC2)
Number of subjects: 10
Study 27550876 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin 500 mg once a day for 3 days after UDS
Number of subjects: 126
Study 27550876 — intervention group
Group type: COMPARATOR
Intervention: Placebo (nontreated patients)
Number of subjects: 126
Study 24877603 — intervention group
Group type: EXPERIMENTAL
Intervention: CHoR protocol (preoperative erythropoietin and iron therapy, intraoperative blood recycling device, lower hemoglobin trigger < 7 g/dl)
Number of subjects: 60
Study 24877603 — intervention group
Group type: EXPERIMENTAL
Intervention: CHoR protocol
Number of subjects: 60
Study 24877603 — intervention group
Group type: COMPARATOR
Intervention: Control group (surgery prior to protocol implementation)
Number of subjects: 60
Study 22369484 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated near-infrared (NIR) light irradiation with fractionated administration of panitumumab-IR700 conjugate
Number of subjects: 0
Study 22369484 — intervention group
Group type: COMPARATOR
Intervention: Single NIR light irradiation
Number of subjects: 0
Study 19660388 — intervention group
Group type: EXPERIMENTAL
Intervention: Bosentan
Number of subjects: 25
Study 19660388 — intervention group
Group type: COMPARATOR
Intervention: No Bosentan
Number of subjects: 25
Study 19808265 — intervention group
Group type: EXPERIMENTAL
Intervention: Nesiritide (2-microg/kg bolus plus 0.01-microg/kg-per-minute infusion for 4 to 6 hours, once or twice weekly for 12 weeks)
Number of subjects: 911
Study 19808265 — intervention group
Group type: COMPARATOR
Intervention: Placebo (matching placebo, once or twice weekly for 12 weeks)
Number of subjects: 911
Study 19808265 — intervention group
Group type: EXPERIMENTAL
Intervention: Nesiritide
Number of subjects: 911
Study 16060245 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular therapy for unruptured cerebral aneurysms
Number of subjects: 76
Study 16060245 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular therapy for aneurysms between 5 to 10 mm
Number of subjects: 76
Study 16060245 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular therapy for aneurysms between 11 to 25 mm
Number of subjects: 76
Study 16060245 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular therapy for aneurysms smaller than 5 mm
Number of subjects: 76
Study 16060245 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular therapy for aneurysms between 5 to 10 mm (follow-up)
Number of subjects: 76
Study 16060245 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular therapy for aneurysms between 10 to 24 mm (follow-up)
Number of subjects: 76
Study 16060245 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular therapy overall
Number of subjects: 76
Study 16060245 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular therapy for a large basilar tip aneurysm
Number of subjects: 76
Study 12353632 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium-chain triacylglycerols (MCTs)
Number of subjects: 11
Study 12353632 — intervention group
Group type: COMPARATOR
Intervention: Long-chain triacylglycerols (blended vegetable oil)
Number of subjects: 11
Study 10364012 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrosternal reconstruction
Number of subjects: 26
Study 10364012 — intervention group
Group type: COMPARATOR
Intervention: Posterior mediastinal reconstruction
Number of subjects: 26
Study 7793449 — intervention group
Group type: EXPERIMENTAL
Intervention: 35% carbon dioxide (CO2) challenge
Number of subjects: 18
Study 1842506 — intervention group
Group type: EXPERIMENTAL
Intervention: 3HEZ2/3HE2 (non‐complicated forms)
Number of subjects: 359
Study 1842506 — intervention group
Group type: EXPERIMENTAL
Intervention: 3HRZ2/3HR2 (complicated forms)
Number of subjects: 359
Study 1842506 — intervention group
Group type: COMPARATOR
Intervention: 6HE2/3H2 (control for non‐complicated forms)
Number of subjects: 359
Study 1842506 — intervention group
Group type: COMPARATOR
Intervention: 3HES2/3HE2/3H2 (control for complicated forms)
Number of subjects: 359
Study 6294004 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased carbohydrate intake from 200 to 400 g
Number of subjects: 6
Study 6294004 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fibre diet rich in beans and lentils
Number of subjects: 6
Study 6294004 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase of dietary fibre to 50 g mainly as cereal fibre
Number of subjects: 6
Study 30852397 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine
Number of subjects: 0
Study 30852397 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29106978 — intervention group
Group type: EXPERIMENTAL
Intervention: The COACH Program (4 or more coaching sessions)
Number of subjects: 512
Study 29106978 — intervention group
Group type: EXPERIMENTAL
Intervention: The COACH Program (up to 3 coaching sessions)
Number of subjects: 512
Study 29106978 — intervention group
Group type: EXPERIMENTAL
Intervention: The COACH Program
Number of subjects: 512
Study 29106978 — intervention group
Group type: EXPERIMENTAL
Intervention: The COACH Program (males)
Number of subjects: 512
Study 29106978 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual care)
Number of subjects: 512
Study 26433700 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral Activation (BA) treatment
Number of subjects: 41
Study 26433700 — intervention group
Group type: COMPARATOR
Intervention: Healthy participants (control group)
Number of subjects: 41
Study 24002616 — intervention group
Group type: EXPERIMENTAL
Intervention: Health coaches providing weight loss counseling
Number of subjects: 26
Study 22057652 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiamine (300 mg/day)
Number of subjects: 9
Study 22057652 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 19605370 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human relaxin
Number of subjects: 328
Study 19605370 — intervention group
Group type: EXPERIMENTAL
Intervention: Type I oral collagen
Number of subjects: 328
Study 19605370 — intervention group
Group type: COMPARATOR
Intervention: Total MRSS
Number of subjects: 328
Study 16755104 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone therapy
Number of subjects: 0
Study 16755104 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended adjuvant therapy, selection of responders using array-based techniques, combination therapy with signal transduction inhibitors
Number of subjects: 0
Study 14690340 — intervention group
Group type: EXPERIMENTAL
Intervention: Iloprost
Number of subjects: 12
Study 14690340 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 10992952 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily practice of three visual tasks (fixation, saccade, and distractor conditions) for 3 to 8 weeks
Number of subjects: 85
Study 10992952 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 85
Study 8865709 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 ml oral water
Number of subjects: 45
Study 8865709 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 ml refreshing drink
Number of subjects: 45
Study 8865709 — intervention group
Group type: COMPARATOR
Intervention: No fluid (control)
Number of subjects: 45
Study 1624025 — intervention group
Group type: EXPERIMENTAL
Intervention: Leuprolide acetate 1.88 mg
Number of subjects: 41
Study 1624025 — intervention group
Group type: EXPERIMENTAL
Intervention: Leuprolide acetate 3.75 mg
Number of subjects: 41
Study 6084920 — intervention group
Group type: EXPERIMENTAL
Intervention: Griseofulvin plus Levamisole
Number of subjects: 26
Study 6084920 — intervention group
Group type: COMPARATOR
Intervention: Griseofulvin plus Placebo
Number of subjects: 26
Study 6084920 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific TR antigen extract stimulation
Number of subjects: 26
Study 6084920 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate weal reactions to TR extract
Number of subjects: 26
Study 6084920 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased concentration of IgE antibodies
Number of subjects: 26
Study 6084920 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific IgG antibodies towards TR
Number of subjects: 26
Study 6084920 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of specific IgG antibodies and strong specific cellular immune response
Number of subjects: 26
Study 6084920 — intervention group
Group type: EXPERIMENTAL
Intervention: Environmental factors and atopy
Number of subjects: 26
Study 30628073 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% O2 (hyperoxia)
Number of subjects: 33
Study 30628073 — intervention group
Group type: COMPARATOR
Intervention: 21% O2 (normoxia)
Number of subjects: 33
Study 28118549 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower-target group (80 to 110 mg/dL)
Number of subjects: 713
Study 28118549 — intervention group
Group type: COMPARATOR
Intervention: Higher-target group (150 to 180 mg/dL)
Number of subjects: 713
Study 28118549 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower-target group
Number of subjects: 713
Study 28118549 — intervention group
Group type: COMPARATOR
Intervention: Higher-target group
Number of subjects: 713
Study 28118549 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 713
Study 26009989 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 weeks of oral antibiotic treatment
Number of subjects: 40
Study 26009989 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 weeks of oral antibiotic treatment
Number of subjects: 40
Study 23647409 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 750 mg
Number of subjects: 8
Study 23647409 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampin 600 mg
Number of subjects: 8
Study 23647409 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 21757386 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive periodontal therapy (IPT)
Number of subjects: 93
Study 21757386 — intervention group
Group type: COMPARATOR
Intervention: Control periodontal therapy (CPT)
Number of subjects: 93
Study 21757386 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive periodontal therapy (IPT) in type 2 DM
Number of subjects: 93
Study 19909203 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone enanthate (TE)
Number of subjects: 40
Study 19909203 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone undecanoate (TU)
Number of subjects: 40
Study 16506873 — intervention group
Group type: EXPERIMENTAL
Intervention: Errorless (implicit) learning strategy
Number of subjects: 22
Study 16506873 — intervention group
Group type: COMPARATOR
Intervention: Discovery (explicit) learning strategy
Number of subjects: 22
Study 14747190 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH analogue (3.75 mg/28 days leuprolide acetate depot) with raloxifene (60 mg/day)
Number of subjects: 100
Study 14747190 — intervention group
Group type: COMPARATOR
Intervention: Placebo (1 tablet/day)
Number of subjects: 100
Study 11574796 — intervention group
Group type: EXPERIMENTAL
Intervention: Diaspirin cross-linked hemoglobin (DCLHb)
Number of subjects: 112
Study 11574796 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 112
Study 9508163 — intervention group
Group type: EXPERIMENTAL
Intervention: More extensive radiotherapy
Number of subjects: 3888
Study 9508163 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy plus chemotherapy
Number of subjects: 3888
Study 7848587 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfuric acid (H2SO4) aerosol (100 micrograms/m3) followed by ozone exposure at 0.08, 0.12, or 0.18 ppm
Number of subjects: 60
Study 7848587 — intervention group
Group type: COMPARATOR
Intervention: Sodium chloride (NaCl) aerosol (control) followed by ozone exposure at 0.08, 0.12, or 0.18 ppm
Number of subjects: 60
Study 2898025 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified diabetic control with continuous subcutaneous insulin infusion (CSII)
Number of subjects: 68
Study 2898025 — intervention group
Group type: COMPARATOR
Intervention: Conventional injection treatment
Number of subjects: 68
Study 30370503 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothetical above average pharmacogenetic response to smoking cessation medication
Number of subjects: 474
Study 30370503 — intervention group
Group type: COMPARATOR
Intervention: Hypothetical below average pharmacogenetic response to smoking cessation medication
Number of subjects: 474
Study 28969404 — intervention group
Group type: EXPERIMENTAL
Intervention: Green tea catechins (600 mg daily for 1 year)
Number of subjects: 60
Study 28969404 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 28969404 — intervention group
Group type: EXPERIMENTAL
Intervention: Green tea catechins
Number of subjects: 60
Study 26242893 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ibandronate (6mg)
Number of subjects: 470
Study 26242893 — intervention group
Group type: COMPARATOR
Intervention: Single-dose radiotherapy (8 Gy)
Number of subjects: 470
Study 26242893 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 470
Study 26242893 — intervention group
Group type: EXPERIMENTAL
Intervention: Retreatment patients
Number of subjects: 470
Study 23931038 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Number of subjects: 3800
Study 23931038 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3800
Study 20563553 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided infiltration
Number of subjects: 60
Study 20563553 — intervention group
Group type: COMPARATOR
Intervention: Conventional palpation technique
Number of subjects: 60
Study 18418314 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast media
Number of subjects: 0
Study 18418314 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant therapy, hydration regimens, choice of contrast agents
Number of subjects: 0
Study 17165278 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate DPI 100 microg every evening
Number of subjects: 296
Study 17165278 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate DPI 100 microg twice daily
Number of subjects: 296
Study 17165278 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 296
Study 17165278 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate DPI (both doses)
Number of subjects: 296
Study 12666704 — intervention group
Group type: EXPERIMENTAL
Intervention: GTR + CPF
Number of subjects: 10
Study 12666704 — intervention group
Group type: COMPARATOR
Intervention: CPF
Number of subjects: 10
Study 11069325 — intervention group
Group type: COMPARATOR
Intervention: Dual therapy (lansoprazole 30 mg o.d. plus amoxicillin 750 mg b.d.)
Number of subjects: 71
Study 11069325 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual therapy plus ecabet sodium (1 g b.d.)
Number of subjects: 71
Study 11069325 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual therapy plus ecabet sodium (2 g b.d.)
Number of subjects: 71
Study 9059199 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofen 1 mg kg-1 i.v. after induction followed by an infusion of ketoprofen 1 mg kg-1 over 2 h
Number of subjects: 164
Study 9059199 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline (placebo)
Number of subjects: 164
Study 8419248 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (1.5 mL = 15 mg)
Number of subjects: 10
Study 3476237 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride varnish (once every 3 months)
Number of subjects: 252
Study 3476237 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride mouthrinse (once a week)
Number of subjects: 252
Study 3476237 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride dentifrice (for home care)
Number of subjects: 252
Study 3476237 — intervention group
Group type: COMPARATOR
Intervention: Placebo mouthrinse (once a week)
Number of subjects: 252
Study 3476237 — intervention group
Group type: COMPARATOR
Intervention: Placebo dentifrice (for home care)
Number of subjects: 252
Study 29473357 — intervention group
Group type: EXPERIMENTAL
Intervention: Zheng's stunt needling technique
Number of subjects: 166
Study 29473357 — intervention group
Group type: COMPARATOR
Intervention: Traditional even needling technique
Number of subjects: 166
Study 27130793 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormonal therapy plus radiation therapy to 70 Gy
Number of subjects: 880
Study 27130793 — intervention group
Group type: COMPARATOR
Intervention: Hormonal therapy alone
Number of subjects: 880
Study 24160900 — intervention group
Group type: EXPERIMENTAL
Intervention: Text message reminders
Number of subjects: 25
Study 24160900 — intervention group
Group type: COMPARATOR
Intervention: No text message reminders (control group)
Number of subjects: 25
Study 22067254 — intervention group
Group type: EXPERIMENTAL
Intervention: MagPro™ (Mg cream)
Number of subjects: 38
Study 22067254 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 19827500 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized home exercise program for acute inversion sprain
Number of subjects: 22
Study 17459550 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 42
Study 17459550 — intervention group
Group type: EXPERIMENTAL
Intervention: Milnacipran
Number of subjects: 42
Study 15782878 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of forms to record residents' wishes about end of life care
Number of subjects: 69
Study 15782878 — intervention group
Group type: EXPERIMENTAL
Intervention: Palliative care policy implementation
Number of subjects: 69
Study 15782878 — intervention group
Group type: EXPERIMENTAL
Intervention: Formal advance directive requirement
Number of subjects: 69
Study 15782878 — intervention group
Group type: EXPERIMENTAL
Intervention: Proxy appointment for residents
Number of subjects: 69
Study 12175666 — intervention group
Group type: EXPERIMENTAL
Intervention: PTCA
Number of subjects: 1018
Study 12175666 — intervention group
Group type: COMPARATOR
Intervention: Medical management
Number of subjects: 1018
Study 9718789 — intervention group
Group type: EXPERIMENTAL
Intervention: Trabucco repair
Number of subjects: 80
Study 9718789 — intervention group
Group type: COMPARATOR
Intervention: Bassini technique
Number of subjects: 80
Study 7663909 — intervention group
Group type: EXPERIMENTAL
Intervention: Transrectal ultrasonography (TRUS) guidance
Number of subjects: 52
Study 7663909 — intervention group
Group type: EXPERIMENTAL
Intervention: Digitally guided systematic biopsies
Number of subjects: 52
Study 2262897 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine 0.5 mg
Number of subjects: 0
Study 2262897 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine 1.0 mg
Number of subjects: 0
Study 2262897 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine 2.0 mg
Number of subjects: 0
Study 2262897 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine 4.0 mg
Number of subjects: 0
Study 2262897 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 65513 — intervention group
Group type: EXPERIMENTAL
Intervention: Pethidine (meperidine) with phenobarbitone
Number of subjects: 6
Study 65513 — intervention group
Group type: COMPARATOR
Intervention: Pethidine (meperidine) without phenobarbitone
Number of subjects: 6
Study 65513 — intervention group
Group type: COMPARATOR
Intervention: Phenobarbitone pretreatment
Number of subjects: 6
Study 65513 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 30557230 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based cognitive prehabilitation
Number of subjects: 61
Study 30557230 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 61
Study 28252875 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical diclofenac (0.1%) four times a day for 7 days before surgery and discontinued 30 days after surgery
Number of subjects: 55
Study 28252875 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical diclofenac (0.1%)
Number of subjects: 55
Study 28252875 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 24874561 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal intermittent positive pressure ventilation (NIPPV) via RAM NC
Number of subjects: 88
Study 24874561 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal continuous positive airway pressure ventilation (NCPAP) via RAM NC
Number of subjects: 88
Study 23144450 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegloticase 8 mg biweekly
Number of subjects: 149
Study 23144450 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegloticase 8 mg monthly
Number of subjects: 149